DURATION OF TREATMENT EFFECT OF MONOCLONAL ANTI-IGE-ANTIBODIES AFTER DISCONTINUATION OF THE THERAPY AND OPPORTUNITIES OF COURSE THERAPY WITH MONOCLONAL ANTI-IGE-ANTIBODIES
https://doi.org/10.18093/0869-0189-2011-0-2-87-91
Abstract
Summary.The study investigated duration of treatment effect of monoclonal anti-IgE-antibodies (omalizumab) after discontinuation of the therapy in asthma patients. The study involved 23 patients treated with monoclonal anti-IgE-antibodies. Daytime and nighttime asthma symptoms, need in rescue medications, daily dose of inhaled steroids (ICS) in beclomethasone equivalents, FEV1, allergy skin tests, quality of life according to AQLQ questionnaire, and asthma control level according to GINA, 2006, were analyzed. Patient-reported control of asthma was evaluated using the Asthma Control test (ACTФ). In 2 months after discontinuation of therapy with monoclonal anti-IgE-antibodies, increase in daytime and nighttime asthma symptoms, need in rescue medications and daily doses of ICS, worsening in asthma control, increase in skin hyperreactivity to domestic and epidermal allergens, and decrease in quality of life were found (all statistically significant). Therefore, the results have shown that monoclonal anti-IgE-antibodies could be administered in discrete regimen; this would allow reduction in frequency of the patient's visits to clinic and in cost of treatment.
About the Authors
Yu. B. Suchkova
ФГУ "НИИ пульмонологии" ФМБА России
Russian Federation
Russian Federation
аспирант
105077, Москва, ул. 11-я Парковая, 32, к. 4
тел.: 8-926-073-92-17
G. L. Osipova
ФГУ "НИИ пульмонологии" ФМБА России
Russian Federation
Russian Federation
д. м. н., ведущий научный сотрудник лаборатории клинической фармакологии
105077, Москва, ул. 11-я Парковая, 32, к. 4
тел. (499) 780-08-14
T. L. Pashkova
ФГУ "НИИ пульмонологии" ФМБА России
Russian Federation
Russian Federation
к. м. н., ведущий научный сотрудник лаборатории функциональных и ультразвуковых методов исследования
105077, Москва, ул. 11-я Парковая, 32, к. 4
тел.: (495) 465-53-84
A. G. Chuchalin
ФГУ "НИИ пульмонологии" ФМБА России
Russian Federation
Russian Federation
д. м. н., акад. РАМН, проф., директор
105077, Москва, ул. 11-я Парковая, 32, к. 4
тел.: (495) 465-52-64
N. P. Knyazheskaya
ФУВ ГОУ ВПО РГМУ Росздрава
Russian Federation
Russian Federation
к. м. н., доцент кафедры пульмонологии
117997, Москва, ул. Островитянова, 1
тел.: (495) 465-83-82
References
1. Global initiative for asthma (GINA). http: //www.ginasthma.com. November 2006.
2. Woolcock A.J., Peat J.K. Evidence for the increase in asthma worldwide. Ciba Found Symp. 1997; 206: 122–134.
3. Ненашева Н.М. Контроль над бронхиальной астмой и возможности его достижения. Пульмонология 2008;3: 91–96.
4. Weel C., Bateman E., Bousquet J. et al. Asthma management pocket reference 2008. Allergy 2008; 63: 997–1004.
5. Черняк Б.А., Воржева И.И. Контролируемое течение бронхиальной астмы как основная цель терапии в повседневной клинической практике. Атмосфера. Пульмонол. и аллергол. 2008; 2: 34–38.
6. Bateman E., Bousley H., Bousquet J. et al. Can guidline-defined asthma control be achieved? Am. J. Respir. Crit.Care Med. 2004; 170: 836–844.
7. Rabe K., Vermeire P., Soriano J., Maier W. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000; 16: 802–807.
8. Partridge M.R., van der Molen T., Myrseth S.E., Busse W.W.Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm. Med.2006; 13: 6–13.
9. Белевский А.С., Вознесенский Н.А. Проблемы контроля бронхиальной астмы у больных, получающих регулярную базисную терапию. Атмосфера. Пульмонол. и аллергол. 2005; 4: 42–44.
10. Чучалин А.Г. (ред.). Рациональная фармакотерапия заболеваний органов дыхания. М.: Литера; 2004. 99–101.
11. Novak N., Bieber T. Allergic and nonallergic forms of atopic diseases. J. Allergy Clin. Immunol. 2003; 112: 252–262.
12. Pearce N., Pekkanen J., Beasley R. How much asthma is really attributable to atopy. Thorax 1999; 54: 268–272.
13. Oettgen H.C., Geha R.S. IgE regulation and roles in asthma pathogenesis. J. Allergy Clin. Immunol. 2001; 107 (3):429–440.
14. Kuhn R. Immunoglobulin E blocade in treatment of asthma. Pharmacotherapy 2007; 27 (10): 1412–1424.
15. Djukanоjvic R., Wilson S., Kraft M. et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit.Care Med. 2004; 170: 583–593.
16. Maykut R.J., Kianifard F., Geba G.P. Response of older patients with IgE-mediated asthma to omalizumab: a pooled analysis. J. Asthma 2008; 45 (3): 173–181.
17. Mossop E.P., Rafi A., Do L., Katz R. Effects of long-term use of omalizumab (Xolair) on pulmonary function testing, quality of life and dependency on concurrent asthma medications. Ann. Allergy 2009; 102: A48.
18. Juniper E.F., O'Byrne P.M., Guyatt G.H. et al. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999; 14 (4): 902–907.
Review
For citations:
Suchkova Yu.B., Osipova G.L., Pashkova T.L., Chuchalin A.G., Knyazheskaya N.P. DURATION OF TREATMENT EFFECT OF MONOCLONAL ANTI-IGE-ANTIBODIES AFTER DISCONTINUATION OF THE THERAPY AND OPPORTUNITIES OF COURSE THERAPY WITH MONOCLONAL ANTI-IGE-ANTIBODIES. PULMONOLOGIYA. 2011;(2):87-91. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-2-87-91
Views:
592
Email this article 